Kornimate/medical-research-clean huggingface dataset:
desflurane and its effect on postoperative morbidity and mortality in patients undergoing thoracic surgery

Conditions: Thoracic Surgery

Summary: desflurane and its effect on postoperative morbidity and mortality in patients undergoing thoracic surgery. halothane, enflurane, isoflurane, sevoflurane, and desflurane are volatile anesthetics, a group of general anesthetics. because of the hypnotic effects of these agents, attention has mainly focused on the central nervous system. in the last 10 years, however, numerous studies have reported that volatile anesthetic agents interact with membrane structures of the myocardium and thereby attenuate cardiac mechanical dysfunction and limit ultrastructural abnormality on reperfusion after prolonged ischemia in the myocyte. anesthetic-induced preconditioning has become a main topic in cardiac research worldwide * trial with medicinal product


Eligibility criteria:
inclusion criteria: • elective thoracic surgery (thoracotomy, thoracoscopy) * lung resection * one-lung ventilation * adults (18-80 years of age) * asa classification i - iii * written consent (signature from patient) exclusion criteria: * known hypersensitivity or suspected allergy to propofol, soja or egg proteins * known hypersensitivity to volatile anesthetics (malignant hyperthermia) * medication with high dosage of statins * therapy with cyclosporin * severe renal impairment (gfr \< 30 ml/min) * oral steroid treatment at present or stopped less than 3 months before surgery * inflammatory processes (non-pulmonary or pulmonary): elevated c-reactive protein level (\> 20 mg/l) or leukocytosis (leukocytes \> 10x103/?l) or body temperature \> 37°c) * pregnancy * breast feeding * the subject must not be involved in any other clinical trial during the course of this trial, nor within a period of 30 days prior to its beginning or 30 days after its completion
prediction of gastric cancer in intestinal metaplasia and atrophic gastritis

Conditions: Gastric Cancer; Intestinal Metaplasia; Atrophic Gastritis

Summary: the primary objectives of this study are: * to identify clinical or histological factors associated with gastric cancer development in patients with im and ag * to establish a machine learning algorithm for prediction of future gastric cancer risks and individual risk stratification in patient with im and ag

this is a two-part retrospective study including a clinical data part and a pathology part. a training cohort will be developed from approximately 70% of included cases. it will be followed by a validation cohort with the remaining cases. clinical data will be collected retrospectively using the clinical data analysis and reporting system (cdars) and clinical management system (cms). a cluster-wide cohort (new territories east cluster, ntec) consisting of patients with history of histologically-proven gastric im and ag will be identified and included for subsequent analysis. the data collection period for the retrospective data will be 2000-2020. histology slides will be retrieved retrospectively when available (within ntec). whole slide imaging technique will be utilized for the development of training and validation cohorts with machine learning algorithms in the pathology part.

Eligibility criteria:
inclusion criteria: * adults \>= 18 years of age * histologically proven atrophic gastritis or intestinal metaplasia (at antrum and/or body and/or angular of stomach) exclusion criteria: - none

Keywords: artificial intelligence
cell-mediated immunity based primary prophylaxis for cmv infection in organ transplant recipients

Conditions: Cytomegalovirus Viraemia

Summary: the study will prospectively determine the clinical utility of cmv cell-mediated immunity using the quantiferon test. the investigators will use the assay results to tailor the duration of cmv prophylaxis in solid organ transplant patients.

cytomegalovirus (cmv) disease is an important cause of morbidity in solid organ transplantation recipients and remains the most common opportunistic viral infection in these patients. standard cmv prevention strategies include universal prophylaxis and pre-emptive therapy with viral load monitoring. however, neither of these strategies has been successful in eliminating cmv disease as seen by high rates of viremia, incidence, and cmv recurrence despite treatment. recently, the quantiferon-cmv assay has been shown to predict late cmv reactivation after prophylaxis and to be predictive of viral progression and the need for antiviral therapy in organ transplant recipients who develop low level cmv viremia. the purpose of the current study is to test the clinical strategy of using the quantiferon-cmv assay in guiding the duration of primary cmv prophylaxis in solid organ transplant patients.

Eligibility criteria:
inclusion criteria: * adult kidney, kidney-pancreas, liver transplant recipient, or heart transplant recipient * cmv d+/r- patient or any r+ patient who received antithymocyte globulin induction therapy exclusion criteria: * unable to comply with protocol * campath (alemtuzumab) induction * receiving another investigational compound for cmv treatment or prophylaxis. * allergy to valganciclovir or ganciclovir * receiving an investigational compound for prevention or treatment of rejection, or participating in another interventional study

Keywords: quantiferon-cmv solid organ transplant cmv disease
detachable string magnetically controlled capsule endoscopy for patients with augib

Conditions: Acute Upper Gastrointestinal Bleeding; Capsule Endoscopes

Summary: use ce for pre-examination of patients with augib symptoms in emergency centers may reduce the need for emergency electronic gastroscopy and have certain advantages in clinical work. patients with low-risk lesions can be discharged without the need for egd and hospitalization, greatly improving the utilization of medical resources.

the investigators plan to conduct exploratory research by sequentially performing ds-mce and egd examinations on augib patients with stable hemodynamics, using egd as the gold standard to evaluate the sensitivity of ds-mce in diagnosing upper gastrointestinal bleeding lesions and active bleeding.

Eligibility criteria:
inclusion criteria: * no gender limit, age ≥ 18 years * presenting to the emergency department with melena or hematemesis * hemodynamically stable at presentation * no endoscopic examination has been performed due to this bleeding * agree to participate in this clinical trial and sign an informed consent form exclusion criteria: * patients with acute active massive bleeding or hemodynamic instability (blood pressure \ 120 beats per minute) * patients with hematochezia * hemodynamics remained unstable after fluid resuscitation * known or suspected intestinal obstruction, stenosis, or fistula * severe motor disorders such as asthma, swallowing disorders, or gastric paralysis * history of abdominal surgery that affects the normal structure of the digestive tract in the past * when capsule retention occurs, the problem cannot be solved through surgery due to subjective or objective reasons * implantable medical devices such as pacemakers, electronic cochlear implants, drug infusion pumps, and neural stimulators are installed inside the body, except for mri compatible products * pregnant women * those who require mri examination before capsule endoscopy discharge * suffering from severe cardiovascular and pulmonary diseases (such as severe myocardial infarction, arrhythmia, heart failure, and respiratory failure) * refuse mce or gastroscopy examination * the researchers believe that the subjects have any other factors that are not suitable for participation in the study

Keywords: augib ds-mce emergency department
schizotypal personality disorder risperidone

Conditions: Schizotypal Personality Disorder

Summary: neurophysiological indices of self-monitoring were assessed in a group of patients with schizotypal personality disorder (spd) and a control group. both groups were assessed after the administration of risperidone and placebo.

the electroencephalogram (eeg) was recorder while participants (spd participants and controls) performed a behavioral task: the eriksen flanker task. the continuous eeg was segmented, corrected for artifacts and averaged. a component of the event-related brain potential known as the error-related negativity (ern) was identified and its amplitude quantified in microvolts. this procedure was conducted two hours after the administration of risperidone 1 mg and placebo (lactose) on two different experimental days and for each participant group (spd patients and controls). the amplitude of the ern after placebo was compared between groups to test for baseline (non-drug-induced) differences between patients and controls. the impact of risperidone on the amplitude of the ern was compared between the two participant groups.

Eligibility criteria:
inclusion criteria: * schizotypal personality disorder exclusion criteria: * major psychiatric disorder * medical condition
prospective study of thoracolumbar spinal fusion graft

Conditions: Lumbar Degenerative Disc Disease

Summary: this study is a single-center, prospective randomized clinical study intended to compare and evaluate the efficacy of subjects who are treated with bone marrow aspirate concentrate (bmac) and allograft to iliac crest bone grafts (icbg) during posterior lumbar/lumbosacral spinal fusion.

subjects who are candidates for posterior lumbar or lumbosacral spinal fusion without anterior interbody support will be screened for inclusion in the study. participants will be enrolled and randomized to either the bmac + allograft or icbg group. an enrollment ratio of two bmac + allograft to one icbg subject (2:1) for up to a total of 40 subjects will be enrolled in the study which also accounts for failed screening subjects. the study will determine and compare differences in fusion rate and health related quality of life parameters at 6 weeks, 3 months, 6 months, 1 year, and 2 years postoperatively.

Eligibility criteria:
inclusion criteria: * must be 18 years old or older * scheduled for elective posterior spinal fusion of the thoracolumbar spine or lumbar spine with or without anterior interbody support * failed at least 6 weeks of conservative care * odi v2.1 score \> 30% * no contraindication to bmac (as per manufacturer) * signed consent form exclusion criteria: * spondylolisthesis grade ≥ 3 * pagets disease, osteomalacia, or any metabolic bone disease * use of medications that interfere with bone healing (chronic steroids) * patient unlikely to comply with post-op schedule with physician * recent history of chemical dependency * participation in other investigational device trial(s) within past 30 days * active malignancy * pregnancy or planning to become pregnant * direct involvement in execution of this protocol
deslorelin combined with low-dose add-back estradiol and testosterone in preventing breast cancer in premenopausal women who are at high risk for this disease

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer

Summary: rationale: chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. deslorelin combined with low-dose add-back estradiol and testosterone (given to replace hormones suppressed by deslorelin) may be effective in preventing breast cancer in at-risk women. purpose: this phase ii trial is studying how well giving deslorelin together with estradiol and testosterone works in preventing breast cancer in premenopausal women who are at high risk for this disease.

objectives: i. assess the effects on the breast of treatment with the gonadotropin-releasing hormone agonist (gnrha)-based regimen in breast cancer (brca) gene mutation carriers, including correlation of changes in mammographic and magnetic resonance imaging (mri) densities with tissue morphometrics and biomarkers. ii. evaluate perspectives about risk reduction options and impact on quality-of-life (qol) measures of participation in the chemopreventive protocol and in risk reduction surgery. outline: group 1: patients receive deslorelin, estradiol, and testosterone intranasally once daily (qd) for 6 months. patients then undergo planned risk reduction mastectomy. group 2: patients receive deslorelin, estradiol, and testosterone intranasally qd for 10 months. patients then undergo continued surveillance through 10 months. after completion of study treatment, patients are followed up every 6 months for 2 years.

Eligibility criteria:
inclusion criteria: * patients must generally be in good health with lab values and physical examination within normal limits * known high risk of breast cancer due to brca mutation or empiric risk \> 30% lifetime by the claus model * no evidence or history of pervious cancer, except non-melanoma skin cancer * premenopausal women planning risk reduction mastectomy in 6 months or more (group 1) or continued surveillance (group 2) * prior tubal ligation or willing to use a non-hormonal barrier method of contraception * signed the informed consent form document for this study in accordance with all federal, state and institutional regulations * must be current non-smoker exclusion criteria: * gnrha treatment within 12 months of study entry * nasal polyposis, atrophic rhinitis, severe allergic or vasomotor rhinitis, or sinusitis requiring current treatment or treatment for more than 3 months in the previous year * concurrent medications including: corticosteroids (prednisone, prednisolone, cortisone acetate, decadron, deltasone, hydrocortisone, hydrocortone, medrol), estrogens, progestins or androgens, including oral, implanted, or injected contraceptive; (at least 6 months must have elapsed since the last use of an implanted or injected contraceptive such as norplant) * pregnant or breast-feeding or have been so in the last six months * immeasurable breast density on mammogram

Keywords: breast cancer brca1 mutation carrier brca2 mutation carrier
effectiveness of frog leg technique in management of low back pain due to lumbar lordosis

Conditions: Low Back Pain, Postural

Summary: condition in which lumbar region experiences stress or extra weight and is arched to point of muscle pain or spasms is called lumbar hyperlordosis.the study findings compared the effectiveness of frog leg technique and standard exercise therapy in management of low back pain due to lumbar lordosis.

in adult population, a major health problem is low back pain. postural change is one of the risk factor. abnormal posture causes strain on ligaments and muscles, as a result indirectly affects the curvature of the lumbar spine.condition in which lumbar region experiences stress or extra weight and is arched to point of muscle pain or spasms is called lumbar hyperlordosis.the study findings compared the effectiveness of frog leg technique and standard exercise therapy in management of low back pain due to lumbar lordosis.

Eligibility criteria:
inclusion criteria: * females with age between 20 and 45 years * patients with low back ache due to lumbar lordosis exclusion criteria: * history of surgery * patients with discogenic backache. * backache in pregnancy. * patients with traumatic history. * patients with pain due to any reason other than lumbar lordosis.

Keywords: low back pain frog leg technique exercise therapy
supervised and home training in fibromyalgia

Conditions: Fibromyalgia

Summary: the goal of this clinical trial is to evaluate the effectiveness of supervised multicomponent training (mct) on physiological parameters, physical fitness, mental well-being, and quality of life in subjects with a history of fibromyalgia, compared to a non-supervised home-based mct protocol and a waitlist control group (wlcg). the main questions it aims to answer are: does supervised mct or non-supervised home-based mct protocol improve physiological parameters, physical fitness, mental well-being, and overall quality of life compared to a waitlist control group (wlcg)? does supervised mct provide superior physiological an psychological improvements compared to a non-supervised home-based mct protocol? researchers will compare: supervised mct (a combination of aerobic, mobility, and resistance training exercises) and non-supervised home-based mct protocol to see if these interventions improve fitness, health, psychological and quality of life outcomes compared to wlcg (participants not engaging in structured physical activity during the study), and if there will be significant differences between supervised mct and non-supervised home-based mct protocol. participants will: complete assessments of anthropometric, physical fitness, and psychological parameters at baseline (t0) and after 12 weeks (t1). be randomly assigned to one of three groups. engage in a 12-week of non-supervised home-based mct protocol or structured mct program supervised by exercise professionals, including: warm-up sessions (10 minutes, low-intensity walking). main sessions (40 minutes): aerobic, mobility, resistance (mct), only-aerobic (at) exercises. cool-down sessions (10 minutes): breathing and stretching exercises. this study will provide insights into the efficacy of tailored physical activity interventions for fibromyalgic patients.


Eligibility criteria:
inclusion criteria: * women/men * diagnosis of fibromyalgia * age between 18 and 75 years at the time of initial treatment; * signature of a written informed consent form (or their legally recognized representatives must sign) indicating that the patient understood the purpose and procedures required for the study and is willing to participate in the study; * sedentary lifestyle (subjects who have not followed who guidelines for aerobic and resistance exercise in the past 3 months); * positive medical specialist assessment of noncompetitive physical activity practice exclusion criteria: * expected absence for more than one week during the intervention period * absence of a medical certificate of suitability for non-competitive sports * severe musculoskeletal or joint disorders with significant mobility limitations * uncontrolled hypertension or untreated heart disease; * pshychiatric disorders;

Keywords: mental and physical well-being anxiety-depressive symptoms fisical fitness
remineralization of early carious lesion using natural agents versus bioadhesive polymers

Conditions: Dental Caries

Summary: this study will be conducted to evaluate: 1. the remineralization potential of natural agents (egg shell powder and clove extract) versus bioadhesive polymers (carbopol and carboxymethyl cellulose) with or without ph cycling using microhardness test. 2. the clinical efficacy of all agents in patients with early carious lesions.


Eligibility criteria:
inclusion criteria: * 1. criteria related to patient: * age's eligible for trial was 18- 30 years. * patient able to read and sign the informed consent form. * cooperative patient who are willing to participate and able to continue the schedule time of wok keep good oral hygiene throughout the study. * healthy volunteers. * patient with moderate and high caries index. 2. criteria related to tooth: * patient with at least 2 white lesions (wsl) detected clinically on the buccal surface of permanent anterior teeth, one on each side. wsl selected either due to caries or orthodontic treatment (just following deboning). * teeth with score1, 2, 3 according to icdas ii. * absence of preoperative pain, no mobility \& tenderness on percussion. * radiographically, the pre-operative inclusion criteria were absence of internal or external resorption, no periapical radiolucencies and no widening of periodontal ligament space.. exclusion criteria: * 1. criteria related to patient: * patient with rampant uncontrolled caries. * patient with compromised medical history. * pregnant or breast feeding females. * heavy smoker. * patient who currently received extensive fluoride regiments for treatment of wsl. * patients who planned to move within 3 months of enrollment. * patient with evidence of xerostomia. 2. criteria related to tooth: * teeth with score 4, 5 according to icdas ii. * teeth with periapical pathology, internal or external resorption or exhibiting any symptoms of pulp pathology. * teeth with questionable vitality or have root canal therapy. * teeth have been pulp capped. * teeth with periodontal pocket and bleeding on probing. * cracked teeth.
phase ii trial of tivozanib in advanced hepatocellular cancer

Conditions: Hepatocellular Cancer

Summary: the purpose of this study is to learn about the effect of the investigational agent tivozanib on the control of the tumor growth in hepatocellular (liver) cancer. the investigators also plan to collect information on the likelihood to develop side effects while on this treatment. tivozanib is an oral medication (pill) taken once a day. this medication is designed to stop the tumor from developing new blood vessels.

angiogenesis is the formation of new blood vessels. angiogenesis is driven by cytokines including vascular endothelial growth factor. tivozanib is an oral medication that inhibits vascular endothelial growth factor preventing tumor from developing new blood vessels. the purpose of this study is to evaluate the effects of tivozanib on hepatocellular (liver) cancer. participants in the study take tivozanib daily at a dose of 1 mg for 1month. if doing well the dose would be increased to 1.5 mg per day. patients are monitored for response using ct or mri scans every 2months. in addition, patients will have blood draws to evaluate the effects of tivozanib on blood vessels.

Eligibility criteria:
inclusion criteria: 1. patients with measurable, histological diagnosis of hepatocellular carcinoma (hcc) and whose disease is not amenable to surgical or regional therapy. 2. prior allowed therapy: * surgery including hepatic resection 1. minimum of 4 weeks since any surgical procedure. 2. patients must have adequately recovered from surgery. * regional therapy 1. includes transarterial chemoembolization (tace), drug-eluting bead \[deb\]-tace, percutaneous ethanol injection, radiofrequency/cryo ablation, yttrium-90 radioembolization. 2. more than 2 weeks must have lapsed from therapy. 3. there must be an indicator lesion outside the treated area or clear evidence of progression in the treated lesion, not amenable for further local therapies. 4. concomitant sorafenib with regional therapy is allowed as long as no evidence of progression on sorafenib. * prior adjuvant sorafenib is allowed, if completed more than 6 months prior to disease recurrence. 3. adequate hematological, liver and metabolic organ function. 4. signed informed consent. exclusion criteria: 1. patients with mixed histology or fibrolamellar variant. 2. prior systemic therapy for metastatic disease. 3. uncontrolled hypertension (htn). 4. symptomatic heart failure.

Keywords: tivozanib advanced hepatocellular cancer angiogenesis